.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Baxter
Novartis
Daiichi Sankyo
Queensland Health
Fuji
Boehringer Ingelheim
Harvard Business School
Colorcon
Federal Trade Commission

Generated: June 25, 2017

DrugPatentWatch Database Preview

IBRANCE Drug Profile

« Back to Dashboard

Which patents cover Ibrance, and what generic Ibrance alternatives are available?

Ibrance is a drug marketed by Pfizer Inc and is included in one NDA. There are three patents protecting this drug.

This drug has sixty-four patent family members in forty-six countries.

The generic ingredient in IBRANCE is palbociclib. Two suppliers are listed for this compound. Additional details are available on the palbociclib profile page.

Summary for Tradename: IBRANCE

Patents:3
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list62
Clinical Trials: see list37
Patent Applications: see list52
Drug Prices:see details
DailyMed Link:IBRANCE at DailyMed

Pharmacology for Tradename: IBRANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-001Feb 3, 2015RXYesNo7,208,489► SubscribeYY ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-002Feb 3, 2015RXYesNo7,208,489► SubscribeYY ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-001Feb 3, 2015RXYesNo► Subscribe► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-003Feb 3, 2015RXYesYes6,936,612► SubscribeYY ► Subscribe
Pfizer Inc
IBRANCE
palbociclib
CAPSULE;ORAL207103-002Feb 3, 2015RXYesNo7,456,168► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: IBRANCE

Country Document Number Estimated Expiration
Serbia59804► Subscribe
South Korea20040077759► Subscribe
Ukraine79444► Subscribe
Dominican RepublicP2003000561► Subscribe
Japan2005519909► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: IBRANCE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017000014Germany► SubscribePRODUCT NAME: PALBOCICLIB, OPTIONAL IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES, ESTERS, AMIDES ODER EINES PRODRUGS HIERVON; REGISTRATION NO/DATE: EU/1/16/1147 20161109
2017013Lithuania► SubscribePRODUCT NAME: PALBOCIKLIBAS, PASIRINKTINAI FARMACINIU POZIURIU PRIIMTINOS DRUSKOS, ESTERIO, AMIDO ARBA PROVAISTO PAVIDALU; REGISTRATION NO/DATE: EU/1/16/1147 20161109
0863Netherlands► SubscribePRODUCT NAME: PALBOCICLIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, ESTER, AMIDE OF PROMEDICIJN DAARVAN; REGISTRATION NO/DATE: EU/1/16/1147 20161111
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Novartis
Julphar
Covington
Mallinckrodt
Chinese Patent Office
Healthtrust
US Army
Accenture
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot